Incyte (NASDAQ: INCY) and BTG (OTCMKTS:BTGGF) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.
Volatility & Risk
Incyte has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, BTG has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.
Insider and Institutional Ownership
92.2% of Incyte shares are held by institutional investors. 17.2% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of current recommendations and price targets for Incyte and BTG, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Incyte presently has a consensus target price of $115.31, indicating a potential upside of 63.37%. Given Incyte’s higher possible upside, analysts clearly believe Incyte is more favorable than BTG.
This table compares Incyte and BTG’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Incyte and BTG’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Incyte||$1.54 billion||9.74||-$313.14 million||$0.64||110.28|
BTG has lower revenue, but higher earnings than Incyte.
Incyte beats BTG on 6 of the 9 factors compared between the two stocks.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and interventional pulmonology products, including PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Specialty Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of envenomations from the copperhead snake; Vistogard for the treatment of 5-fluorouracil toxicity; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup for hip joint replacement; and Lemtrada for treatment of multiple sclerosis. The company also manufactures and commercializes therapeutic ultrasound devices. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.